Related Experiment Video
Updated: Aug 28, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
Lowering Uric Acid May Improve Prognosis in Patients With Hyperuricemia and Heart Failure With Preserved Ejection
Masami Nishino1, Yasuyuki Egami1, Shodai Kawanami1
1Division of Cardiology Osaka Rosai Hospital Osaka Japan.
Insights
High uric acid (UA) predicts worse outcomes in heart failure with preserved ejection fraction (HFpEF) patients with hyperuricemia. Lowering UA levels may improve prognosis and reduce mortality or rehospitalization in this population.
Area of Science:
- Cardiology
- Nephrology
- Internal Medicine
Background:
- An association between uric acid (UA) and cardiovascular diseases, including heart failure (HF), is established.
- The causal role of UA in HF and its prognostic value in HF with preserved ejection fraction (HFpEF) remain controversial.
- The impact of lowering UA in patients with hyperuricemia and HFpEF is not well understood.
Purpose of the Study:
- To investigate the correlation between uric acid (UA) levels and adverse cardiovascular events in patients with hyperuricemia and HFpEF.
- To evaluate the prognostic value of lowering UA in this patient cohort.
- To assess whether reducing UA levels impacts all-cause mortality and HF rehospitalization.
Main Methods:
- Analysis of 464 patients with hyperuricemia (UA >7.0 mg/dL) from the PURSUIT-HFpEF registry.
- Multivariable Cox regression analysis to determine UA's association with composite endpoints (all-cause mortality and HF rehospitalization).
- Comparison of outcomes between groups with severe vs. mild hyperuricemia and between those who lowered UA vs. those who did not.
Main Results:
- UA was an independent determinant of composite death and rehospitalization in patients with hyperuricemia and HFpEF (HR, 1.15).
- Severe hyperuricemia was associated with significantly higher all-cause mortality compared to mild hyperuricemia (HR, 1.73).
- Lowering UA levels over one year significantly decreased the incidence of all-cause mortality (HR, 1.71), with a trend towards increased urate-lowering therapy use.
Conclusions:
- Uric acid is a significant predictor of composite death and HF rehospitalization in patients with hyperuricemia and HFpEF.
- Lowering uric acid levels, potentially through urate-lowering therapy, may offer a therapeutic strategy to improve prognosis in this population.
- Further research is warranted to confirm the benefits of UA reduction in HFpEF management.
Abstract:
Background An association between uric acid (UA) and cardiovascular diseases, including heart failure (HF), has been reported. However, whether UA is a causal risk factor for HF is controversial. In particular, the prognostic value of lowering UA in patients with HF with preserved ejection fraction (HFpEF) is unclear. Methods and Results We enrolled patients with HFpEF from the PURSUIT-HFpEF (Prospective Multicenter Observational Study of Patients With Heart Failure With Preserved Ejection Fraction) registry. We investigated whether UA was correlated with the composite events, including all-cause mortality and HF rehospitalization, in patients with hyperuricemia and HFpEF (UA >7.0 mg/dL). Additionally, we evaluated whether lowering UA for 1 year (≥1.0 mg/dL) in them reduced mortality or HF rehospitalization. We finally analyzed 464 patients with hyperuricemia. In multivariable Cox regression analysis, UA was an independent determinant of composite death and rehospitalization (hazard ratio [HR], 1.15 [95% CI, 1.03-1.27], P=0.015). We divided them into groups with severe and mild hyperuricemia according to median estimated value of serum UA (8.3 mg/dL). Cox proportional hazards models revealed the incidence of all-cause mortality was significantly higher in the group with severe hyperuricemia than in the group with mild hyperuricemia (HR, 1.73 [95% CI, 1.19-2.25], P=0.004). The incidence of all-cause mortality was significantly decreased in the group with lowering UA compared with the group with nonlowering UA (HR, 1.71 [95% CI, 1.02-2.86], P=0.041). The incidence of urate-lowering therapy tended to be higher in the group with lowering UA than in the group with nonlowering UA (34.9% versus 24.6%, P=0.06). Conclusions UA is a predictor for the composite of all-cause death and HF rehospitalization in patients with hyperuricemia and HFpEF. In these patients, lowering UA, including the use of urate-lowering therapy, may improve prognosis.
More Related Videos
10:02Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril
Published on: October 3, 2020
07:09A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure Drugs: Diuretics
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Atherosclerosis III: Management
Heart Failure VI: Adjunct Therapies
Rheumatic Heart Disease III: Medical Management